Effectiveness of Fingolimod spurred the generation of other S1P1 subtype-specific modulators for the treatment of MS, inflammatory bowel disease, psoriasis, and systemic lupus erythematosus25,41–44. Here, S1PR1 is linked to myeloid sarcoma.